ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2274

Assessment Of The Diagnostic Accuracy Of Different Strategies For Health Fair Case-Finding For Undiagnosed Inflammatory Arthritis

Kaylynn Aiona1, Christopher C. Striebich2, M. Kristen Demoruelle3, Julia J. Rhiannon4, Stuart M. Weisman5, Marie L. Feser3, Lezlie A. Derber5, James H. Goddard6, Stacey Brake6, Jill Lysengen7, Laura Rosseisen7, John E. Hokanson1, Anna E. Baron1, Jill M. Norris8, V. Michael Holers9 and Kevin D. Deane3, 1Colorado School of Public Health, Aurora, CO, 2University of Colorado Denver, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Rheumatology, University of Colorado School of Medicine, Aurora, CO, 5University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 69Health Fair, Denver, CO, 7Arthritis Foundation, Great West Region, Denver Office, Denver, CO, 8Epidemiology, Colorado School of Public Health, Aurora, CO, 9Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Community programs, Diagnostic Tests, Inflammatory arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  

Early treatment of inflammatory arthritis (IA), and especially rheumatoid arthritis (RA), leads to improved outcomes, although diagnostic delays may impede timely treatment. We hypothesized that case finding in a community based health fair may improve the timing of diagnosis and treatment of IA. However, the diagnostic accuracy of this approach in a health fair where IA is likely rare is largely unknown. Therefore, we developed and tested the diagnostic accuracy of a case-finding strategy for IA in a Colorado-based health fair.

Methods:  

Volunteers were evaluated between 2009-2012 at 18 health fair sites using a self-reported joint symptom questionnaire and CCP3 (INOVA; ≥20 units positive) and RF (Roche RFII; >14 units positive) testing. IA was defined as synovitis identified by a trained clinician on examination of the wrists, elbows, and PIP and MCP joints performed at the same time as the questionnaire and blood testing.

Results:  

3260 volunteers completed a questionnaire, joint examination and blood testing; 164 (5%) were identified with active, previously undiagnosed IA, of whom 33/164 (20%) were classified as RA by 2010 ACR/EULAR criteria. After modifications of an initial questionnaire to improve its ease of use and sensitivity for IA, the optimal prediction model for IA (multiple regression; bootstrap validated AUC of 0.73) included 4 items that each contributed similarly to the model: CCP positivity and self-reported: a) morning stiffness ≥1 hour, b) nodules, and c) joint pain, stiffness or swelling present the day of questionnaire completion. The maximal sensitivity (SENS) for IA was with ≥1 item positive (96%; corresponding specificity (SPEC) of 24%); ≥2 positive items resulted in the highest combination of SENS and SPEC (85% and 52%, respectively). In 2012 we piloted a questionnaire with a figure for subjects to identify symptom location, and symptoms in PIPs and MCPs were 93% SENS and 65% SPEC for IA, although there were too few cases of IA (N=15 out of 338 subjects) to evaluate adequately the diagnostic accuracy of additional factors. CCP and/or RF were positive in 279/3260 (9%) of subjects, and both autoantibodies (Abs) were independently significantly associated with IA (p<0.01 and 0.03, respectively). In evaluation of the diagnostic accuracy of Abs alone for IA, CCP and/or RF positivity was 11% SENS and 92% SPEC for IA, reflecting that most IA was seronegative. Additionally, CCP and RF levels >3 times normal were each highly specific for IA (CCP: SENS 5%, SPEC 99%; RF: SENS 5%, SPEC 99%).

Conclusion:  

Assessing self-reported symptoms and Abs in a health fair may identify previously undiagnosed IA/RA. As such, these items may be used initially independently of a clinician thus broadening the applicability of this approach to settings where trained joint examiners are absent. Further testing is necessary to validate these findings and to determine whether case-finding accuracy may be improved by ascertaining specific locations of joint symptoms. Additionally, determining final formal diagnoses, timing of treatment for IA, and post-health fair costs (including costs of evaluating false-positive results) will help determine the overall impact of this approach in arthritis care.


Disclosure:

K. Aiona,
None;

C. C. Striebich,
None;

M. K. Demoruelle,
None;

J. J. Rhiannon,
None;

S. M. Weisman,
None;

M. L. Feser,
None;

L. A. Derber,
None;

J. H. Goddard,
None;

S. Brake,
None;

J. Lysengen,
None;

L. Rosseisen,
None;

J. E. Hokanson,
None;

A. E. Baron,
None;

J. M. Norris,
None;

V. M. Holers,
None;

K. D. Deane,

AbbVie,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-diagnostic-accuracy-of-different-strategies-for-health-fair-case-finding-for-undiagnosed-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology